In brief
On 3 May 2024, the European Medicines Agency (EMA) published new Q&As for applicants, marketing authorization holders of medicinal products, and notified bodies on the implementation of the EU Regulations on medical devices and in vitro diagnostic medical devices (i.e., EU Regulations 2017/745 and 2017/746).
Key takeaways
The new Q&As are based on the experience gained from the application of the regulations and the specific cases encountered so far, and aim at providing practical considerations on the relevant implementation, with particular reference to those products that consist of a combination of medicinal products with medical devices.
In particular, the Q&A contains regulatory and procedural guidance in relation to (i) medical devices that form an integral product with a medicinal product and their life-cycle management, (ii) medicinal product that include a medical device in their packaging and the relevant modalities to label them, (iii) the consultation procedure for ancillary medicinal substances that are integral part of medical devices, and (iv) the consultation procedure for companion diagnostics.